At the request of the US Food and Drug Administration, Abbott Laboratories Inc has agreed to withdraw its obesity drug, Meridia (sibutramine), from the US market because of clinical trial data indicating an increased cardiovascular risk. ---Subscribe to MedNous to access this article--- Company News Regulation & Policy
